Non-Invasive Molecular Imaging of β-Adrenoceptors In Vivo: Perspectives for PET-Radioligands
The β-adrenoceptor (β-AR) radioligands discussed in this review represent a class of molecular probes for the non-invasive in vivo assessment of β-AR density eg. in the heart with PET. The β-AR radioligands (S)- [11C]CGP 12177 (1) or (S)-[11C]CGP 12388 (2) are currently investigated in clinical studies with PET. Additionally, subtype-selective b1-AR radioligands are used in preclinical research which show potential for the diagnostics of the "β1-AR organ" as such the heart can be defined. Non-invasive quantification of β-ARs could facilitate the accurate choice and control of therapeutic interventions. Here we summarize the state-ofthe- art of the radiochemistry of radioactive β-AR radioligands.
Keywords: adrenoceptor radioligand; diagnostics in nuclear medicine; molecular imaging; positron emission tomography pet; receptor imaging in vivo; scintigraphy; subtype-selective b-adrenoceptor radioligand
Document Type: Review Article
Affiliations: Department of Nuclear Medicine, Section Radiochemistry, University Hospital of the Westfalische Wilhelms-Universitat, Albert-Schweitzer-Str. 33, D-48149 Munster, Germany.
Publication date: 01 August 2005
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.